Latest Ratios: P/E Ratio -12.0x · EV/EBITDA N/A · ROE -11.3%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $513M | $417M | $535M | $737M | $832M | $1.2B | $745M | $687M | $438M | $92M | — |
| Enterprise Value | $594M | $497M | $572M | $716M | $824M | $1.2B | $741M | $643M | $399M | $75M | — |
| P/E Ratio → | -12.01 | — | — | — | 673.39 | — | — | — | — | — | — |
| P/S Ratio | 2.17 | 1.76 | 2.61 | 4.96 | 6.81 | 11.76 | 10.48 | 9.47 | 7.62 | 2.03 | — |
| P/B Ratio | 1.37 | 1.20 | 1.51 | 1.96 | 2.20 | 5.12 | 3.17 | 4.83 | 5.36 | 1.95 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.10 | 2.79 | 4.82 | 6.74 | 11.96 | 10.43 | 8.86 | 6.93 | 1.65 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.1% | 73.1% | 72.6% | 74.8% | 74.1% | 74.9% | 77.4% | 75.3% | 74.2% | 75.5% | 70.7% |
| Operating Margin | -12.3% | -12.3% | -14.4% | -18.0% | -20.8% | -18.4% | -37.6% | -12.5% | -16.6% | -14.2% | -16.4% |
| Net Profit Margin | -16.8% | -16.8% | -18.5% | -14.1% | 1.0% | -16.6% | -46.3% | -18.9% | -20.9% | -19.6% | -17.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -11.3% | -11.3% | -10.3% | -5.6% | 0.4% | -7.1% | -17.5% | -12.3% | -18.6% | -33.4% | -75.9% |
| ROA | -8.1% | -8.1% | -8.3% | -4.8% | 0.3% | -5.1% | -12.7% | -9.0% | -12.4% | -15.8% | -21.4% |
| ROIC | -5.3% | -5.3% | -5.9% | -5.5% | -6.2% | -5.7% | -12.2% | -9.7% | -19.7% | -18.6% | -21.6% |
| ROCE | -6.4% | -6.4% | -7.1% | -6.7% | -7.5% | -6.3% | -11.4% | -6.4% | -10.9% | -13.4% | -25.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.29 | 0.29 | 0.23 | 0.03 | 0.00 | 0.13 | 0.11 | 0.18 | 0.26 | 0.54 | 2.93 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.23 | 0.10 | -0.06 | -0.02 | 0.09 | -0.02 | -0.31 | -0.48 | -0.36 | 2.66 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -4.86 | -4.86 | -11.26 | — | -8.99 | -7.95 | -8.87 | -2.59 | -4.33 | -2.59 | -3.45 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.55 | 5.55 | 6.98 | 5.44 | 7.34 | 4.50 | 4.52 | 9.37 | 10.54 | 7.35 | 2.87 |
| Quick Ratio | 2.65 | 2.65 | 3.54 | 2.90 | 4.81 | 2.56 | 3.01 | 6.59 | 7.75 | 5.18 | 0.82 |
| Cash Ratio | 1.32 | 1.32 | 2.03 | 1.93 | 3.83 | 1.85 | 2.43 | 5.18 | 6.58 | 4.50 | 0.22 |
| Asset Turnover | — | 0.46 | 0.43 | 0.34 | 0.29 | 0.32 | 0.22 | 0.37 | 0.51 | 0.55 | 1.22 |
| Inventory Turnover | 0.48 | 0.48 | 0.48 | 0.35 | 0.40 | 0.43 | 0.30 | 0.47 | 0.58 | 0.54 | 0.73 |
| Days Sales Outstanding | — | 83.14 | 75.52 | 84.95 | 74.02 | 66.79 | 90.12 | 83.35 | 60.25 | 44.83 | 40.10 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | 6.5% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 0.1% | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.1% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 7.5% | — |
| Shares Outstanding | — | $23M | $23M | $23M | $21M | $19M | $18M | $15M | $13M | $5M | $8M |
Liquidity and capital constraints
According to recent market data, KIDS trades at a price-to-sales multiple of 2.17, which appears elevated given the company's decelerating revenue growth and persistent inability to generate positive net income compared to more established orthopedic peers like Globus Medical that maintain significantly higher profitability profiles.
The current valuation suggests that investors are pricing in a long-term growth narrative rather than immediate earnings, effectively ignoring the lack of a positive P/E ratio. This premium may be difficult to justify if the company fails to demonstrate a clear path to operational scale and margin expansion in the coming quarters.
Based on reported financial statements, OrthoPediatrics has consistently delivered negative ROIC, with figures hovering around -1.6% in 2026Q1, indicating that the company is currently destroying rather than compounding shareholder capital as it continues to fund its specialized pediatric distribution model through persistent operating losses.
The negative return on invested capital reflects the heavy burden of capitalized surgical instrument sets that have yet to reach sufficient utilization levels to generate adequate returns. Investors should monitor whether the company can improve its asset turnover, as the current trend suggests that capital deployment is not yet yielding the expected efficiency gains.
As reported in financial filings, the company's cash conversion cycle remains exceptionally high, reaching 728 days in 2026Q1, primarily driven by a bloated inventory turnover period that highlights the significant capital tied up in specialized surgical kits placed across various hospital locations for potential future use.
This extended cycle suggests that the company's 'razor-blade' business model is highly capital-intensive and requires substantial upfront investment before any revenue is realized. The inability to shorten this cycle indicates that the company may face continued pressure on its liquidity position as it attempts to scale its footprint.
Based on the most recent quarterly data, the current ratio has compressed to 5.21 from higher historical levels, which, when combined with a dwindling cash balance of $19.5M, suggests a tightening liquidity position that leaves the firm increasingly vulnerable to unexpected operational shocks or prolonged cash burn.
While the current ratio appears superficially healthy, the high inventory dependence and the nature of consignment assets mean that liquidity is not as readily available as the headline number might imply. The company's reliance on external financing to cover its negative cash flow warrants close investigation by stakeholders.
Market participants frequently overemphasize the company's 73% gross margin as a sign of operational strength, yet this metric obscures the reality that the high cost of maintaining and deploying specialized surgical instrument sets creates a structural drag that prevents the company from achieving meaningful bottom-line profitability.
Investors should instead focus on the operating margin and free cash flow conversion, as these metrics better capture the true cost of the company's distribution model. Relying on gross margin alone ignores the significant logistical and capital expenses required to support the pediatric-only surgical niche.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KIDS stock.
OrthoPediatrics Corp.'s current P/E ratio is -12.0x. This places it at the 50th percentile of its historical range.
OrthoPediatrics Corp.'s return on equity (ROE) is -11.3%. The historical average is -24.9%.
Based on historical data, OrthoPediatrics Corp. is trading at a P/E of -12.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
OrthoPediatrics Corp. has 73.1% gross margin and -12.3% operating margin.